Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders were woefully unhedged by several measures, leaving them vulnerable to feel the brunt of the stock's 20% drop. …
Even though Celgene Corporation (NASDAQ:CELG) presents itself as changing the course of human health through bold pursuits in science, CELG stock is not acting that way. The shares have lost almost 16% since the company reported …
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market caps over $50 billion. And now, …
Celgene (NASDAQ: CELG) stock has been in my investment portfolio since 2013. I enjoyed a couple of great years with the biotech stock performing really well. Over the past couple of years, however, Celgene hasn't generated high …
Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more. Celgene's past success stemmed primarily from four drugs: Revlimid, Pomalyst, …
Celgene (NASDAQ: CELG) has long garnered one of the richest valuations among large-cap biotechs, and for good reason. The long and short of it is that Celgene has been able to post industry-leading levels of revenue growth year …
Celgene, a major biotech company, said on Thursday that it planned to stop developing a critical drug. The drug, …
As the broader market rallied on Tuesday on the back of hopeful rhetoric around tax reform, the healthcare sector happily participated. The biotechnology subgroup of stocks also flocked higher, leaving plenty of so-called “bullish reversals” …